Equities Analysts Issue Forecasts for LFST Q1 Earnings

LifeStance Health Group, Inc. (NASDAQ:LFST) – Stock analysts at William Blair issued their Q1 2025 earnings estimates for shares of LifeStance Health Group in a note issued to investors on Thursday, February 27th. William Blair analyst R. Daniels anticipates that the company will post earnings per share of ($0.03) for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for LifeStance Health Group’s current full-year earnings is ($0.18) per share. William Blair also issued estimates for LifeStance Health Group’s Q2 2025 earnings at ($0.03) EPS, Q3 2025 earnings at ($0.02) EPS, Q4 2025 earnings at ($0.02) EPS and FY2025 earnings at ($0.10) EPS.

Other analysts have also recently issued reports about the company. The Goldman Sachs Group raised LifeStance Health Group from a “neutral” rating to a “buy” rating and set a $10.00 price objective for the company in a research report on Monday, December 16th. Barclays upped their price objective on shares of LifeStance Health Group from $6.00 to $7.00 and gave the stock an “underweight” rating in a research report on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $8.70.

LifeStance Health Group Stock Up 1.4 %

LFST opened at $8.02 on Monday. The stock has a market capitalization of $3.07 billion, a P/E ratio of -30.85 and a beta of 1.28. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.32 and a current ratio of 1.32. LifeStance Health Group has a one year low of $4.64 and a one year high of $8.61. The business’s 50-day simple moving average is $7.83 and its 200-day simple moving average is $7.27.

Hedge Funds Weigh In On LifeStance Health Group

Hedge funds and other institutional investors have recently bought and sold shares of the company. Jennison Associates LLC lifted its stake in LifeStance Health Group by 278.4% in the 4th quarter. Jennison Associates LLC now owns 8,086,380 shares of the company’s stock valued at $59,597,000 after buying an additional 5,949,438 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of LifeStance Health Group by 87.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 3,524,529 shares of the company’s stock worth $25,977,000 after buying an additional 1,643,390 shares in the last quarter. Vanguard Group Inc. boosted its position in LifeStance Health Group by 7.9% during the fourth quarter. Vanguard Group Inc. now owns 10,689,396 shares of the company’s stock worth $78,781,000 after acquiring an additional 784,818 shares during the last quarter. Geode Capital Management LLC boosted its position in LifeStance Health Group by 26.8% during the third quarter. Geode Capital Management LLC now owns 3,452,178 shares of the company’s stock worth $24,170,000 after acquiring an additional 729,794 shares during the last quarter. Finally, Wellington Management Group LLP raised its holdings in LifeStance Health Group by 15.2% in the 3rd quarter. Wellington Management Group LLP now owns 4,830,441 shares of the company’s stock valued at $33,813,000 after acquiring an additional 638,385 shares during the last quarter. 85.50% of the stock is owned by institutional investors and hedge funds.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.